Full Text View
Tabular View
No Study Results Posted
Related Studies
A Pilot Study to Assess the Follow-up of Prostate Cancer Patients Who Have Undergone Radiotherapy Treatment (PROFUGO)
This study is currently recruiting participants.
Study NCT00823771   Information provided by Barwon Health
First Received: January 14, 2009   Last Updated: July 6, 2009   History of Changes

January 14, 2009
July 6, 2009
October 2007
 
 
 
Complete list of historical versions of study NCT00823771 on ClinicalTrials.gov Archive Site
 
 
 
A Pilot Study to Assess the Follow-up of Prostate Cancer Patients Who Have Undergone Radiotherapy Treatment
A Pilot Study in the Transfer of Follow-up Reviews to the General Practitioner for Prostate Cancer Patients Who Have Undergone Radiotherapy Treatment

This is a pilot study assessing the role of the general practitioner in performing follow-up reviews on men who have recently completed radical radiotherapy for prostate cancer. This will be measured primarily by assessing any changes to the patient's health-related quality of life which will be evaluated by the completion of questionnaires by the participant at each review visit. The study aims to confirm that patient outcome is identical, independent of whether follow-up is performed by a specialist or the patient's General Practitioner.

 
 
Observational
Case Control, Prospective
Prostate Cancer
 
 
 

*   Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
 
Recruiting
112
 
 

Inclusion Criteria:

  • Men with a tumour T1-3 stage prostate cancer and have had radical radiotherapy with curative intent
  • Are between six and twelve months post-treatment completion
  • Have completed all treatment for prostate cancer (including hormonal deprivation therapy)
  • Have no evidence of metastatic disease
  • ECOG performance status of between 0-1
  • Remains willing to comply with study requirements
  • Has maintained contact with an individual general practitioner

Exclusion Criteria:

  • Persistent complications resulting from treatment defined as a minimum Grade 3 treatment toxicity
  • Unable to complete self-administered questionnaires
  • Are currently enrolled in a study that requires specialist follow-up
  • Life expectancy of less than 6 months
  • Surgery to remove the prostate
  • Evidence of biochemical failure
Male
 
No
Contact: Elaine Yeow, BSc, MHN 61-3-52267858 elainey@barwonhealth.org.au
Australia
 
NCT00823771
 
ALCC 07.01
Barwon Health
 
Principal Investigator: Rodney Lynch, BMedSc, MBBS Barwon Health
Barwon Health
July 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP